In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally ailment progression or even the individuals are not able to tolerate the study drugs. - "Our study discovered the vital role on the KLF16/MYC regulatory https://johne333pbl5.sunderwiki.com/user